Nitric Acid

Nitric Acid

SCHEMBL29355529

Cc1cccc(Cl)c1NC1=NCCN1.O=[N+]([O-])O

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ERG11

The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 9/20 0.64
ADRA2C P18825 8/20 0.64
ADRA2B P18089 7/20 0.64
ADRA1A P35348 6/20 0.64
HTR1D P28221 5/20 0.64
ADRA1D P25100 4/20 0.64
ADRA1B P35368 4/20 0.64
LMNA P02545 4/20 0.64
NISCH Q9Y2I1 3/20 0.64
CYP2D6 P10635 2/20 0.64
HRH2 P25021 2/20 0.64
MEN1 O00255 1/20 0.64
SLC22A1 O15245 1/20 0.64
SLC22A3 O75751 1/20 0.64
HTR1A P08908 1/20 0.64
CYP2C9 P11712 1/20 0.64
CYP2C19 P33261 1/20 0.64
OPRK1 P41145 1/20 0.64
KMT2A Q03164 1/20 0.64
HIF1A Q16665 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11176814 0.90 ADRA2A (0.79) ADRA2AADRA2CADRA2BADRA1AHTR1D
Clonidine SCHEMBL5983 0.80 ADRA2A (1.00) ADRA2AADRA2CADRA2BADRA1AHTR1D
SCHEMBL4760243 0.80 HTR1D (1.00) ADRA2AADRA2CADRA2BADRA1AHTR1D
Hydrochloric Acid SCHEMBL29384552 0.78 HTR1D (0.97) ADRA2AADRA2CADRA2BADRA1AHTR1D
Clonidine SCHEMBL9838990 0.78 ADRA2A (0.97) ADRA2AADRA2CADRA2BADRA1AHTR1D
Clonidine SCHEMBL2231324 0.78 ADRA2A (1.00) ADRA2AADRA2CADRA2BADRA1AHTR1D
Clonidine SCHEMBL613364 0.78 ADRA2A (0.97) ADRA2AADRA2CADRA2BADRA1AHTR1D
Clonidine SCHEMBL40752 0.78 ADRA2A (1.00) ADRA2AADRA2CADRA2BADRA1AHTR1D
Clonidine SCHEMBL18050245 0.78 ADRA2A (0.82) ADRA2AADRA2CADRA2BADRA1AHTR1D
SCHEMBL17887765 0.76 HTR1D (0.79) ADRA2AADRA2CADRA2BADRA1AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230309480-A1 METHODS OF INCREASING OUTCROSSING RATES IN GRAMINEAE INTERNATIONAL RICE RESEARCH INSTITUTE (PH) 2023-10-05 US claimed
EP-4199703-A1 METHODS OF INCREASING OUTCROSSING RATES IN GRAMINEAE International Rice Research Institute (PH) 2023-06-28 EP claimed
WO-2022038536-A1 METHODS OF INCREASING OUTCROSSING RATES IN GRAMINEAE INTERNATIONAL RICE RESEARCH INSTITUTE (PH) 2022-02-24 WO claimed
US-20260127545-A1 SIMULATION MODEL GENERATION METHOD, SIMULATION MODEL GENERATION PROGRAM, AND SIMULATION MODEL GENERATION SYSTEM PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) 2026-05-07 US disclosed
US-12611461-B2 Bioorthogonal compositions TAMBO, INC. (US) 2026-04-28 US disclosed
US-20260079462-A1 METHOD OF MANAGING MANUFACTURING LINE KIOXIA CORPORATION (JP) 2026-03-19 US disclosed
US-20260072513-A1 Sensory Control Method, Sensory Control System, Method For Generating Conversion Model, Conversion Model Generation System, Method For Converting Relational Expression, And Program ALPS ALPINE CO LTD (JP) 2026-03-12 US disclosed
WO-2026042565-A1 AUTHENTICATION SYSTEM, INFORMATION PROCESSING METHOD FOR AUTHENTICATION SYSTEM, AND PROGRAM フェリカネットワークス株式会社 2026-02-26 WO disclosed
US-12551959-B2 Solder supply unit, solder piece manufacturing device, part mounting device, and production system HIRATA CORPORATION (JP) 2026-02-17 US disclosed
US-20260045791-A1 ELECTRICAL LINE SELECTOR SYSTEM HAVING MULTIPLE SOURCES RELECTRIFY HOLDINGS PTY LTD (AU) 2026-02-12 US disclosed
US-12504826-B2 Sensory control method, sensory control system, method for generating conversion model, conversion model generation system, method for converting relational expression, and program ALPS ALPINE CO., LTD. (JP) 2025-12-23 US disclosed
WO-2022091322-A1 SERVER SELECTION DEVICE AND SERVER SELECTION SYSTEM 三菱電機株式会社 2022-05-05 WO disclosed
WO-2022092199-A1 ADHESIVE TAPE 積水化学工業株式会社 2022-05-05 WO disclosed
US-20220119352-A1 BIS-CYCLIC GUANIDINES AS ANTIBACTERIAL AGENTS NATIONAL SCIENCE FOUNDATION 2022-04-21 US disclosed
CN-114340680-A Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy 坦博公司 2022-04-12 CN disclosed
US-11281914-B2 Vehicle monitoring system and vehicle monitoring method PANASONIC I-PRO SENSING SOLUTIONS CO., LTD. (JP) 2022-03-22 US disclosed
EP-3960729-A1 COMPOUNDS AND METHODS OF TREATING INFECTIONS Neoculi Pty Ltd (AU) 2022-03-02 EP disclosed
WO-2022038536-A1 METHODS OF INCREASING OUTCROSSING RATES IN GRAMINEAE INTERNATIONAL RICE RESEARCH INSTITUTE (PH) 2022-02-24 WO disclosed
US-11253600-B2 Bioorthogonal compositions TAMBO, INC. (US) 2022-02-22 US disclosed
US-11230524-B2 Myocyte enhancer factor 2 (MEF2) modulators STANDARD LLC (US) 2022-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11230524-B2 Myocyte enhancer factor 2 (MEF2) modulators MEF2D, MYLK2, TNNT2 ADRA2A 789/4885ADRA2C 713/4885ADRA2B 583/4885
US-20220119352-A1 BIS-CYCLIC GUANIDINES AS ANTIBACTERIAL AGENTS GMPS, CGAS, GDA ADRA2A 1941/4885ADRA2C 1761/4885ADRA2B 1397/4885
US-20260072513-A1 Sensory Control Method, Sensory Control System, Method For Generating Conversion Model, Conversion Model Generation System, Method For Converting Relational Expression, And Program TRRAP, PIEZO1, L1CAM ADRA2A 1824/4885ADRA2C 1371/4885ADRA2B 2029/4885
US-20260127545-A1 SIMULATION MODEL GENERATION METHOD, SIMULATION MODEL GENERATION PROGRAM, AND SIMULATION MODEL GENERATION SYSTEM ATP5PO, TIMM44, IPO11 ADRA2A 2387/4885ADRA2C 2771/4885ADRA2B 3509/4885
US-12611461-B2 Bioorthogonal compositions ACVRL1, FCGR2A, CHIT1 ADRA2A 1930/4885ADRA2C 1387/4885ADRA2B 1383/4885
US-12551959-B2 Solder supply unit, solder piece manufacturing device, part mounting device, and production system WAPL, CUTA, LANCL2 ADRA2A 4516/4885ADRA2C 4811/4885ADRA2B 4622/4885
US-11253600-B2 Bioorthogonal compositions TIE1, BBOX1, ST14 ADRA2A 3331/4885ADRA2C 3196/4885ADRA2B 3477/4885
US-20260079462-A1 METHOD OF MANAGING MANUFACTURING LINE MOK, THPO, MRPL9 ADRA2A 3170/4885ADRA2C 4197/4885ADRA2B 3733/4885
US-20260045791-A1 ELECTRICAL LINE SELECTOR SYSTEM HAVING MULTIPLE SOURCES MCU, SET, PC ADRA2A 3229/4885ADRA2C 3053/4885ADRA2B 3860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.